Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1220 results
April 2016
-
Media Release
Novartis a enregistré un premier trimestre solide, malgré la perte d'exclusivité de Gleevec, et investi dans de nouveaux lancements pour soutenir la croissance à long terme
Chiffre d'affaires net en hausse de 1% (tcc[1]), les produits de croissance ayant compensé l'impact du générique de Gleevec Les produits de croissance[2] ont progressé de 24% (en USD) à USD 3,9… -
Media Release
Novartis drug Afinitor® significantly reduces seizures in Phase III study of patients with tuberous sclerosis complex
Everolimus is the first adjunctive therapy shown in a prospective randomized Phase III study to achieve clinically significant seizure control in TSC patients[1] Seizures are the most… -
Media Release
Sandoz receives EC approval for subcutaneous route of administration in biosimilar Binocrit's® nephrology indication
Sandoz' epoetin alfa product offering has already generated more than 400,000[1] patient years of experience worldwide EC approval expands Sandoz biosimilar offering to the healthcare community… -
Media Release
Novartis receives EU approval for Revolade® as first-in-class therapy for children aged 1 year and above with chronic ITP
EU approval of Revolade expands treatment options for pediatric patients aged 1 year and above with chronic ITP who have not responded to other therapies Two formulations approved: once-daily… -
Media Release
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless...
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless of prior heart…
March 2016
-
Media Release
Novartis publishes updated 2015 segment financials reflecting new division structure
Updated segment financials reflect transfer of Ophthalmic Pharmaceuticals franchise from Alcon to Pharmaceuticals, and 19 mature products from Pharmaceuticals to Sandoz, as outlined in Q4 and FY… -
Media Release
Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks
New data at AAD 2016 shows Cosentyx® is significantly more efficacious than Stelara in sustaining skin clearance (PASI 90 to PASI 100) at 52 weeks[1] Cosentyx delivered and sustained skin…
February 2016
-
Media Release
FDA approves new indication for Novartis drug Afinitor® for progressive, nonfunctional GI and lung neuroendocrine tumors (NET)
In advanced progressive, nonfunctional NET, Afinitor is the first approved treatment for patients with lung NET and the first oral therapy for GI NET Approval helps fulfill unmet need as… -
Media Release
Novartis shareholders approve all resolutions proposed by Board of Directors
Shareholders approve 19th consecutive dividend increase to CHF 2.70 (+4%) per share for 2015 Dr. Joerg Reinhardt confirmed by shareholders as Chairman of the Novartis Board of Directors as well as… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration
Les actionnaires approuvent la 19e hausse consécutive du dividende, à CHF 2,70 par action (+4%) au titre de l'exercice 2015. Le Dr Joerg Reinhardt est confirmé par les actionnaires dans ses fonctions… -
Media Release
Novartis Aktionäre genehmigen alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2015 die 19. Dividendenerhöhung in Folge auf CHF 2,70 pro Aktie (+4%) Dr. Jörg Reinhardt als Präsident des Novartis Verwaltungsrats ebenso wie alle weiteren Mitglieder des… -
Media Release
Novartis drug PKC412 (midostaurin) receives Breakthrough Therapy designation from the FDA for newly-diagnosed FLT3-mutated acute myeloid leukemia (AML)
PKC412 (midostaurin) significantly improved overall survival of adult patients eligible to receive standard induction and consolidation chemotherapy AML has the lowest survival rate of all adult…